- Home
- GPUS vs UPB Comparison
GPUS vs UPB Comparison
Compare GPUS & UPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPUS
- UPB
- Stock Information
- Founded
- GPUS 1969
- UPB 2021
- Country
- GPUS United States
- UPB United States
- Employees
- GPUS N/A
- UPB N/A
- Industry
- GPUS
- UPB
- Sector
- GPUS
- UPB
- Exchange
- GPUS NYSE
- UPB NYSE
- Market Cap
- GPUS 4.8M
- UPB 521.3M
- IPO Year
- GPUS 1996
- UPB 2024
- Fundamental
- Price
- GPUS $1.34
- UPB $11.19
- Analyst Decision
- GPUS
- UPB Strong Buy
- Analyst Count
- GPUS 0
- UPB 4
- Target Price
- GPUS N/A
- UPB $56.50
- AVG Volume (30 Days)
- GPUS 2.6M
- UPB 536.5K
- Earning Date
- GPUS 08-15-2025
- UPB 08-14-2025
- Dividend Yield
- GPUS N/A
- UPB N/A
- EPS Growth
- GPUS N/A
- UPB N/A
- EPS
- GPUS N/A
- UPB N/A
- Revenue
- GPUS $93,318,000.00
- UPB $2,296,000.00
- Revenue This Year
- GPUS N/A
- UPB N/A
- Revenue Next Year
- GPUS N/A
- UPB N/A
- P/E Ratio
- GPUS N/A
- UPB N/A
- Revenue Growth
- GPUS N/A
- UPB N/A
- 52 Week Low
- GPUS $1.23
- UPB $5.14
- 52 Week High
- GPUS $11.73
- UPB $29.46
- Technical
- Relative Strength Index (RSI)
- GPUS N/A
- UPB N/A
- Support Level
- GPUS N/A
- UPB N/A
- Resistance Level
- GPUS N/A
- UPB N/A
- Average True Range (ATR)
- GPUS 0.00
- UPB 0.00
- MACD
- GPUS 0.00
- UPB 0.00
- Stochastic Oscillator
- GPUS 0.00
- UPB 0.00
About GPUS HYPERSCALE DATA INC
Hyperscale Data Inc, formerly Ault Alliance Inc is a diversified holding company. It operates a data center at which it mines Bitcoin and provides mission-critical products that support a diverse range of industries, including oil exploration, crane services, defense/aerospace, industrial, automotive, medical/biopharma, consumer electronics, hotel operations and textiles. The company has six reportable segments: Energy and Infrastructure; Technology and Finance; Sentinum, Inc.; GIGA; TurnOnGreen; ROI; and Ault Global Real Estate Equities, Inc.
About UPB UPSTREAM BIO INC
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.